Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
HARROW, INC. reported second quarter 2023 results: revenue in excess of $31.0 million.
- Period
- second quarter 2023
- Revenue
- in excess of $31.0 million
- Result
- preliminary results
Exact text from the filing
Management expects the Company to record over $31,000,000 of total revenues and over $9,300,000 of Adjusted EBITDA (a non-GAAP measure) for the three-month period ended June 30, 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
HARROW, INC. reported second quarter 2023 results: revenue in excess of $31.0 million.
- Period
- second quarter 2023
- Revenue
- in excess of $31.0 million
- Result
- preliminary results
Exact text from the filing
Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 million
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HARROW, INC. amended Oaktree Amendment with Oaktree Fund Administration, LLC valued at from $100,000,000 to $112,500,000 (effective 2023-07-18).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Oaktree Fund Administration, LLC
- Value
- from $100,000,000 to $112,500,000
- Effective
- 2023-07-18
Exact text from the filing
On July 18, 2023, Harrow Health, Inc. (the "Company") entered into the First Amendment to Credit Agreement and Guaranty and Consent (the "Oaktree Amendment") to the Credit Agreement and Guaranty (the "Oaktree Loan") originally entered into on March 27, 2023, with the lenders from time to time party thereto and Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, "Oaktree"). Under the Oaktree Amendment, the overall credit facility size was increased from $100,000,000 to $112,500,000, and the Company made other changes related to the Santen Products Acquisition
View on SEC.gov